Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University: clinical-trial pipeline
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University is the sponsor of 477 clinical trials in ClinicalTrials.gov and the EU CTIS portal; 224 are not yet finished and 12 were first posted in the last 90 days. Source: Arcadium Data, data as of .
Open trials224
Phase 2/3 and 340
Countries2
New in 90 days12
Trials by phase
| Phase | Trials |
|---|---|
| Not applicable | 294 |
| Phase 2 | 103 |
| Phase 3 | 35 |
| Phase 4 | 14 |
| Phase 1/2 | 12 |
| Phase 1 | 10 |
| Phase 2/3 | 5 |
| Early phase 1 | 4 |
Trials by status
| Status | Trials |
|---|---|
| Unknown | 182 |
| Recruiting | 121 |
| Not yet recruiting | 82 |
| Completed | 67 |
| Active, not recruiting | 21 |
| Suspended or halted | 2 |
| Terminated | 1 |
| Withdrawn or not authorised | 1 |
Condition areas
| Area | Trials |
|---|---|
| Oncology | 297 |
| Women's health and obstetrics | 52 |
| Nephrology and urology | 37 |
| Cardiovascular | 33 |
| Gastroenterology and liver | 27 |
| Neurology | 23 |
| Metabolic and endocrine (diabetes, obesity) | 21 |
| Infectious disease and vaccines | 17 |
| Immunology and rheumatology | 11 |
| Rare and genetic diseases | 10 |
| Dermatology | 8 |
| Psychiatry and mental health | 7 |
Countries
| Country | Trials |
|---|---|
| China | 395 |
| United States | 1 |
Latest changes
| Day | Change | Trial |
|---|---|---|
| 2026-10-23 | New trial posted | Trastuzumab Rezetecan Followed by Pyrotinib, Fulvestrant, and Dalpiciclib in HR-Positive,… |
| 2026-10-19 | New trial posted | Multimodal Liquid-Biopsy Omics Biomarkers of Treatment Response in Breast Cancer |
| 2026-10-16 | New trial posted | Autologous Circulating Extracellular Vesicles for Total-Type Sudden Sensorineural Hearing… |
| 2026-10-14 | New trial posted | MRG003 Added to Ongoing Treatment After Progression in EGFR-Positive Advanced Thyroid Can… |
| 2026-10-02 | New trial posted | Venipuncture Via Nurse-AI Collaboration |
| 2026-10-02 | New trial posted | Arsenic Trioxide Combined With Chemotherapy for Relapsed SHH-Activated and/or TP53-Mutant… |
| 2026-10-01 | New trial posted | DV Plus Toripalimab With Cetirizine and Mecobalamin Pretreatment in Patients With Locally… |
| 2026-09-08 | New trial posted | Anlotinib + Benmelstobart + HAIC in Unresectable HCC: A Phase II Study |
| 2026-09-08 | New trial posted | Early Endotoxin Burden Reduction With oXiris in Septic Shock Patients Requiring CRRT |
| 2026-09-03 | New trial posted | Efficacy and Safety of Anrikefon Injection for Multimodal Postoperative Analgesia in Pati… |
| 2026-09-01 | New trial posted | Neoadjuvant Culmerciclib Combined With Endocrine Therapy for Hormone Receptor-Positive， H… |
| 2026-08-31 | New trial posted | Efficacy Analysis of Transcutaneous Auricular Vagus Nerve Stimulation Combined With Tailo… |
Open trials
The 25 most recently changed open trials.
| Registry id | Title | Phase | Status | Countries |
|---|---|---|---|---|
| NCT05980702 | 4 Courses vs 2 Courses of Pembrolizumab Combined With Carboplatin and Albumin-binding Paclitaxel of Neoadjuva… | Phase 2 | Recruiting | China |
| NCT06440083 | Pre-warning Risk Scoring System for Sudden Cardiac Death | Not applicable | Recruiting | China |
| NCT05204108 | Preoperative Detection of Muscle Invasion in Bladder Cancer with Contrast-enhanced Ultrasonography | Not applicable | Recruiting | China |
| NCT06121557 | Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast C… | Phase 1 | Recruiting | China |
| NCT06607107 | mFOLFOX7 Plus Camrelizumab and Apatinib in BCLC Stage A/B Hepatocellular Carcinoma Patients Beyond Milan Crit… | Phase 2 | Recruiting | China |
| NCT07874321 | MRG003 Added to Ongoing Treatment After Progression in EGFR-Positive Advanced Thyroid Cancer | Phase 2 | Recruiting | China |
| NCT07679997 | Trilaciclib Combined With Immunochemotherapy for R/M HNSCC | Phase 2 | Not yet recruiting | |
| NCT07239622 | Liposomal Irinotecan Combined With Sintilimab and Anlotinib in the Treatment of Recurrent or Persistent Ovari… | Phase 2 | Not yet recruiting | |
| NCT07856069 | Arsenic Trioxide Combined With Chemotherapy for Relapsed SHH-Activated and/or TP53-Mutant Medulloblastoma | Phase 2 | Not yet recruiting | China |
| NCT06313463 | Study Of Capecitabine Combined With Camrelizumab For Non-pCR TNBC With TLS After Neoadjuvant Chemoterapy | Phase 3 | Recruiting | China |
| NCT06925516 | A Trial of Apatinib and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable ICC | Phase 2 | Recruiting | China |
| NCT07708207 | Development and Validation of an AI Foundation Model for Frozen-Section Pathology | Not applicable | Active, not recruiting | China |
| NCT07794462 | Efficacy Analysis of Transcutaneous Auricular Vagus Nerve Stimulation Combined With Tailor-Made Notched Music… | Not applicable | Not yet recruiting | China |
| NCT06161779 | Submental Flap for the Reconstruction of Hypopharyngectomy | Not applicable | Recruiting | China |
| NCT07606807 | rhTNK-tPA for Acute Ischemic Stroke Under Simplified Imaging in the Extended Time Window | Phase 3 | Recruiting | China |
| NCT06843681 | Trastuzumab Plus Taxane Neoadjuvant Therapy for HER2-Positive Breast Ductal Carcinoma In Situ (DCIS) : A Phas… | Phase 2 | Recruiting | China |
| NCT07119996 | Clinical Trial on the Protective Role of Vitamin B3 in Enhancing Immunotherapy for Bladder Cancer Patients | Phase 1 | Recruiting | China |
| NCT05159193 | Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuz… | Phase 3 | Recruiting | China |
| NCT07051083 | Bladder Cancer Staging and Prediction of New Adjuvant Chemotherapy Efficacy Based on Deep Learning and Transf… | Not applicable | Recruiting | China |
| NCT06365008 | Sintilimab Plus FOLFIRI as Second-line Therapy for Patients With HER2-negative Advanced Gastric Cancer | Phase 2 | Not yet recruiting | China |
| NCT06883955 | Clinical Features and Current Treatment of Primary Headache | Not applicable | Not yet recruiting | China |
| NCT06933394 | Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma | Phase 2 | Recruiting | China |
| NCT07728955 | A Single-arm, Exploratory Clinical Study Evaluating the Efficacy and Safety of Bevacizumab in Combination Wit… | Phase 3 | Not yet recruiting | |
| NCT05869058 | DCNN Developed for Detection and Assessing the Perfusion of PTG | Not applicable | Recruiting | China |
| NCT07536165 | Extended Time Window Intravenous Tenecteplase Thrombolysis Registry for Acute Ischemic Stroke | Not applicable | Not yet recruiting | China |
All sponsors: clinical-trial pipeline by sponsor.
Track a sponsor's pipeline
The API returns the same trials by sponsor website, phase, status, condition and country with a change feed, joined to hiring and public contract awards. Try it without a key on one sponsor.
Sources: ClinicalTrials.gov (U.S. National Library of Medicine, public domain) and the EU Clinical Trials Information System public portal (European Medicines Agency), data as of 2026-10-25. A trial that one register cites in the other is shown once. Organisation-level data only: investigators, contact persons and site names are not stored, and a sponsor that could be a private person is withheld. Sponsor-to-website matches are made by name and can be wrong; check the register before relying on a record. Independent of the NLM, NIH and EMA.
Cite as: Arcadium Data, "Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University clinical trials: 224 open, 40 in phase 3", https://arcadiumdata.io/clinical-trials/sponsor/sun-yat-sen-memorial-hospital-of-sun-yat-sen-university/, data as of 2026-10-25.